These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 32861620

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
    Carvalho J, Nunes P, Da Silva ET, Silva R, Lima J, Quaresma V, Figueiredo A.
    Arch Ital Urol Androl; 2021 Mar 18; 93(1):21-25. PubMed ID: 33754603
    [Abstract] [Full Text] [Related]

  • 5. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G, Detti B, Bottero M, Zilli T, Lancia A, Bruni A, Borghesi S, Mariotti M, Castellucci P, Fanti S, Filippi AR, Teriaca MA, Maragna V, Aristei C, Mazzeo E, Livi L, Ingrosso G.
    Clin Transl Oncol; 2021 Feb 18; 23(2):364-371. PubMed ID: 32602076
    [Abstract] [Full Text] [Related]

  • 6. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments.
    Devos G, Witters M, Moris L, Van den Broeck T, Berghen C, Devlies W, De Meerleer G, Goffin K, Jentjens S, Albersen M, Van Poppel H, Everaerts W, Joniau S.
    World J Urol; 2021 Feb 18; 39(2):399-406. PubMed ID: 32417995
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 18; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B, Farag M, Liodakis P, Angus D, Lim Joon D, Bolton D.
    BJU Int; 2021 May 18; 127 Suppl 1():23-29. PubMed ID: 33973332
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive].
    Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN.
    Prog Urol; 2017 May 18; 27(8-9):474-481. PubMed ID: 28576423
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients.
    Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V, Foca F, Nicolini S, Giganti M, Paganelli G, Matteucci F.
    Eur J Nucl Med Mol Imaging; 2021 Jan 18; 48(1):87-94. PubMed ID: 32588090
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy.
    Raveenthiran S, Yaxley J, Gianduzzo T, Kua B, McEwan L, Wong D, Tsang G, MacKean J.
    Prostate Cancer Prostatic Dis; 2019 Sep 18; 22(3):385-390. PubMed ID: 31363165
    [Abstract] [Full Text] [Related]

  • 18. The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Ga-PSMA-11 PET in prostate cancer.
    Aydos U, Çetin S, Akdemir ÜÖ, Budak FÇ, Ateş SG, Koparal MY, Gönül İI, Gülbahar Ö, Sözen S, Atay LÖ.
    Prostate; 2021 Dec 18; 81(16):1337-1348. PubMed ID: 34516677
    [Abstract] [Full Text] [Related]

  • 19. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May 18; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.